-
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialRidker PM, MacFadyen JG, CANTOS Trial Group et al. -
Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of MorbidityKhan SS, Ning H, Wilkins JT et al.
-
Dynamic atrioventricular delay programming improves ventricular electrical synchronization as evaluated by 3D vectorcardiographyEB Engels, B Thibault, FW Prinzen et al.
-
Management of Percutaneous Coronary Intervention Complications: Algorithms From the 2018 and 2019 Seattle Percutaneous Coronary Intervention Complications ConferenceJA Doll , RS Hira , KE Kearney et al.
-
Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents 2-Year Clinical Outcomes: From the BIONICS and NIREUS TrialsM Konigstein, PC Smits, MP Love et al.
-
Individualizing Revascularization Strategy for Diabetic Patients With Multivessel Coronary DiseaseM Qintar, KH Humphries, JE Park et al.
-
Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and BeyondLibby P
-
The Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk CalculatorA Khera , MJ Budoff , CJ O’Donnell et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
